Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of vinflunine plus capecitabine versus capecitabine alone in advanced breast cancer resistant to anthracyclines and taxanes
2008-004171-21Phase 3Terminated
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jan 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Javlor plus capecitabine with Capecitabine alone (2 arms). Primary endpoint: progression-free survival. Started Jan 2009; status: terminated.
02
Drugs
vinfluninecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-004171-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004171-21.